Secondary outcomes included metabolic and hepatic parameters such as serum lipids (total cholesterol, LDL, high-density lipid (HDL), triglycerides), fasting glucose and insulin, insulin resistance indices (homeostatic model assessment of insulin resistance (HOMA-IR), triglyceride-glucose index (TyG)), and liver markers (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), fibrosis index based on 4 factors (FIB-4), controlled attenuation parameter (CAP), liver stiffness. This evidence concerns the gene GPT and Insulin resistance.